MannKind Corporation (MannKind) USA developed and produces the medication Afrezza, which is designed to help adult patients with diabetes mellitus achieve better glycemic control.
Cipla's stock price:Investors were keeping an eye on Cipla's stock on Thursday, December 12, after the pharmaceutical giant said on Wednesday that it had been given permission by the Central Drugs Standard Control Organization to distribute and promote Afrezza inhalation powder in India.
MannKind Corporation (MannKind) USA developed and produces the medication Afrezza, which is designed to help adult patients with diabetes mellitus achieve better glycemic control.
According to a statement from the Mumbai-based corporation, Cipla will make this medication available to everyone and enable millions of people to take charge of their health more easily by introducing a revolutionary, patient-centered approach to diabetes care in India.
Unlike existing insulins, which are administered as injections, Afrezza is a rapid-acting insulin that is administered via inhalation.
The drug's action, which is similar to how the body reacts to insulin, lasts for roughly two to three hours.
Unlike existing insulins, which are administered as injections, Afrezza is a rapid-acting insulin that is administered via inhalation.
The drug's action, which is similar to how the body reacts to insulin, lasts for roughly two to three hours.
According to the pharmaceutical company, this is the first and only non-injectable insulin created for those with type 1 and type 2 diabetes.
"By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively," Umang Vohra, MD and Global CEO of Cipla,
Results of Cipla Q2 FY25
"By reducing the need for multiple daily insulin injections, we are offering a convenient solution for people living with diabetes mellitus, particularly those who are uncomfortable with needles, helping them manage their condition more effectively," Umang Vohra, MD and Global CEO of Cipla,
Results of Cipla Q2 FY25
Due to strong sales in all areas, pharmaceutical giant Cipla announced on Tuesday a 17% increase in consolidated net profit to ₹1,303 crore for the second quarter that ended in September 2024.
In the July–September quarter of the previous fiscal year, the company generated a net profit of ₹1,115 crore.
According to Cipla's regulatory filing, its overall operating income increased to ₹7,051 crore in the second quarter from ₹6,490 crore in the same period last year.
Umang Vohra, MD and Global CEO of Cipla, stated, "In Q2 FY25, we recorded a revenue growth of 9% over the last year with the highest-ever EBITDA margin of 26.7% driven by mix and other operational efficiencies."
In the July–September quarter of the previous fiscal year, the company generated a net profit of ₹1,115 crore.
According to Cipla's regulatory filing, its overall operating income increased to ₹7,051 crore in the second quarter from ₹6,490 crore in the same period last year.
Umang Vohra, MD and Global CEO of Cipla, stated, "In Q2 FY25, we recorded a revenue growth of 9% over the last year with the highest-ever EBITDA margin of 26.7% driven by mix and other operational efficiencies."
0 Comments